Skip to content

2017 – February – Blind Item 2

    The other blind item we have for you today is about this planned sequel that never took off. It’s sad to see that all this was a hoax to make money. Well, now that their secret is out, we hope the investors get their money back.

     

    Bollywood Blind Item

    2017 - February - Blind Item 2

    A multi-starrer with big names that was announced as a sequel to a hit film by a successful director and a producer with a dubious reputation seems to be shelved.

    Says a source, “It was never going to be made. The lavish announcement with big faces was only to attract finance. The actors also know this. And they got big money to be part of this charade. A senior most actor got paid a whopping Rs.5 crore. Some of the actors whose clippings were played during the launch were not even part of the film, or ever intended to be. There is no script. No dates have been taken. But the producer continues to plant stories about the progress of the film, to keep the money rolling.

     

    OSOP Guesses

    Sequel: Ankhen 2

    Senior Actor: Amitabh Bachchan

    2017 - February - Blind Item 2

    6 thoughts on “2017 – February – Blind Item 2”

    1. OMG. How can they be so mean and scammers. Big b is seriously going bankrupt if he wants to cheat people. We all know he’s not going to get a penny from abhishek hahahaha

    2. Why not Hera Pheri 3? Absolutely fuckall going on, but it’s been rumbling about in the underbelly of Bollywood gossip columns every three weeks.

      1. because it can not be Hera Peri was many rumors about this fact, but no one has not officially announced the casting, no one did a press conference with film actors, nobody did speculation on names, while Tamanna filed even in court on organizers Ankhen 2 for the using her name.

    3. heck! I was angry on Akshay, who was not part of the sequel! In fact, he simply refused to be part of this farce, I would be wrong in relation to my Akki ( here is a new blind. very interesting who is this?

    Comments are closed.